Ann: Strategic Review of Cynata Clinical Development Portfolio, page-5

The big news from this is the 300 recruitment rate for Sculptor (so glad new management recognising immediately, the importance of updating the market - that bodes well). That's slightly ahead of my expectations - they do describe accelerated enrolment this year. The rest we knew/expected.

Whilst the detractors continue to easily bag the stock with our self declared HC Field Marshall out of action with a spot of gout/dysentery/syphilis (who knows?) this should not be overlooked. Even our previous omnipotent and ever optimistic 'leader' had expectations not too far off this:

"Looks like 220 + now as indicates first week FEB.5 a week and we're done by end 2023."

Not quite the 340-350 he and other more optimistic holders might have hoped for by now, but if presently 300 and they manage 7 a week for 2023, then they are indeed done on recruitment by 2023, as clearly they have stated in their DFU trial too.

Expectations are a little hard to grasp at this micro end of the mkt, but against the exhausting gloom and doom detraction of CYP on HC, this news clearly has a few good information points.